BeiGene's novel BCL2 inhibitor, Sonrotoclax, receives first-in-world approval for relapsed/refractory mantle cell lymphoma treatment.
The first-in-world approval of Sonrotoclax is a landmark event for BeiGene and a significant development for cancer patients globally, particularly in APAC where B-cell malignancies are prevalent. This approval validates BeiGene's R&D capabilities and its commitment to bringing innovative therapies to market. It offers a new hope for patients with limited treatment options and strengthens BeiGene's position in the oncology landscape.
Sonrotoclax approved globally for R/R MCL.
First-in-world approval for BeiGene's novel BCL2 inhibitor.
Offers new treatment option for B-cell malignancy patients.
This approval is highly relevant to APAC as it provides a novel treatment option for patients with B-cell malignancies in the region. BeiGene's strong presence in APAC means this drug will likely be a key focus for market access and patient support programs, addressing a critical unmet medical need in countries like China and others across Asia.
First-in-world approval for BeiGene's novel BCL2 inhibitor.
Offers new treatment option for B-cell malignancy patients.
Sign in to save notes on signals.
Sign In